Compare Abeona Therapeutics Inc (ABEO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Charles River Laboratories Intl. Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Charles River Laboratories Intl. Inc trades at $222.49 (market cap $11.01B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 29.5× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | CRL | |
|---|---|---|
Market Cap | $373.32M | $11.01B |
Sector | Health | Health |
52-Week High | $7.23 | $231.43 |
52-Week Low | $4.17 | $145.57 |
Enterprise Value | $228.22M | $13.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CRL trades at $228.68, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported negative net income of -$144.34M in 2025 despite revenue stability around $4.02B, resulting in a high P/E of 684.85. Recent earnings beats and strategic collaborations, such as with Lilly TuneLab (Business Wire, 2026-06-18), highlight operational strengths amid profitability challenges.
Outlook is mixed: strong analyst support (72% buy ratings) and positive cash flow trends contrast with negative margins and high debt. Key risks include sustained unprofitability and competitive pressures, but institutional confidence and technical momentum suggest potential for recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
